5-HT1A receptor subtype agonist

Details 5-HT1A receptor subtype agonist 5-HT1A receptor subtype agonist

2004-06-28

2011-10-04

Anderson, James (Department: 1629)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

08030312

ABSTRACT:
The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1Areceptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1):wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

REFERENCES:
patent: 4734416 (1988-03-01), Banno et al.
patent: 4764416 (1988-08-01), Ueyama et al.
patent: 4983607 (1991-01-01), Manoury et al.
patent: 5006528 (1991-04-01), Oshiro et al.
patent: 5073377 (1991-12-01), Alexander et al.
patent: 5162375 (1992-11-01), Nicholson et al.
patent: 5200410 (1993-04-01), Traber et al.
patent: 5385914 (1995-01-01), Fujioka et al.
patent: 5504093 (1996-04-01), Gelfand et al.
patent: 5652247 (1997-07-01), Ogawa et al.
patent: 5691330 (1997-11-01), Nakao et al.
patent: 5824680 (1998-10-01), Turner et al.
patent: 6267942 (2001-07-01), Mori et al.
patent: 7053092 (2006-05-01), Jordon et al.
patent: 2002/0076437 (2002-06-01), Kothari et al.
patent: 2003/0027817 (2003-02-01), Tollefson
patent: 2002226752 (2002-08-01), None
patent: 29 12 105 (1985-08-01), None
patent: 29 12 105 (1985-08-01), None
patent: 0 226 441 (1987-06-01), None
patent: 0 360 077 (1990-03-01), None
patent: 0 367 141 (1990-05-01), None
patent: 0 565 274 (1993-10-01), None
patent: 0 776 927 (1997-06-01), None
patent: 54-130587 (1979-10-01), None
patent: 56-46812 (1981-04-01), None
patent: 2-191256 (1990-07-01), None
patent: A-70135 (1995-03-01), None
patent: 9-40648 (1997-02-01), None
patent: 11-508280 (1997-10-01), None
patent: 9 301 867 (1997-11-01), None
patent: 9-291034 (1997-11-01), None
patent: 09 301867 (1997-11-01), None
patent: 11-509865 (1997-11-01), None
patent: 11-335286 (1999-12-01), None
patent: WO 92/10200 (1992-06-01), None
patent: WO 92/20655 (1992-11-01), None
patent: WO 93/04681 (1993-03-01), None
patent: WO 94/09765 (1994-05-01), None
patent: WO 94/13620 (1994-06-01), None
patent: WO 98/07426 (1998-02-01), None
patent: WO 98/08817 (1998-03-01), None
patent: WO 99/38864 (1999-08-01), None
patent: WO 99/52870 (1999-10-01), None
patent: WO 02/102297 (2002-12-01), None
patent: WO 03/026659 (2003-04-01), None
patent: WO 03/030868 (2003-04-01), None
Vippagunta et al. Adv. Drug Del. Rev., vol. 48, (2001), pp. 3-26.
Sheehan et al. Acta Psychiatr. Scand., 1993, vol. 88, No. 1, pp. 1-11 (Abstract attached).
Poltronieri et al. Behavioral Brain Research, 2003, vol. 147, pp. 185-192.
Aouizerate et al. Neuropsychiatric Disease and Treatment, 2005, vol. 1, No. 3, pp. 231-243.
Fujii et al. Prog. Neuropsychopharmacol. Biol. Psychiatry, Nov. 28, 2009, Issue 1878-4216 (Abstract attached).
Garattini et al. Clin. Neuropharmacol., 1988, vol. 11, suppl. 1, pp. S8-S32 (Abstract attached).
Gentile, Neuropsychiatric Disease and Treatment, 2009, vol. 5, pp. 117-125.
Kohen et al. Am. J. Ther., 2009, vol. 16, No. 2, pp. 197-198 (Abstract attached).
Manfredi et al. Am. J. Psychiatry, 1991, vol. 148, No. 9, pp. 1213-1217 (Abstract attached).
Lykouras et al. European Neuropsychopharmacology, 2000, vol. 10, pp. 385-387.
Lykouras et al. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2003, vol. 27, pp. 333-346.
McDougle et al. The American Journal of Psychiatry, 1996, vol. 152, No. 12, pp. 1812-1814 (Abstract attached).
Eric P.M. Prinssen et al., Interactions between neuroleptics and 5-HT1Aligands in preclinical behavioral models for antipsychotic and extrapyramidal effects, Psychopharmacology, vol. 144, No. 1, May 1999, pp. 20-29.
Uwahodo Yasufumi et al., “Pharmacological profile of OPC-14597, a novel antipsychotic drug (2); Weak extrapyramidal side effects.” Japanese Journal of Pharmacology, vol. 67, No. Suppl. 1, 1995, p. 144P.
S. Jordan et al., “In Vivo Effects of Aripiprazole on Dopaminergic and Serotonergic Function in Rat Prefrontal Cortex and Striatum.” Society for Neuroscience Abstracts, Society of Neurosciene, US, vol. 2., No. 27, 2001, p. 2327, AN87503.
Jeffery A. Lieberman, “Atypical Antipsychotic Drugs as a First-Line Treatment of Schizophrenia: A Rationale and Hypothesis,” Journal of Clinical Psychiatry, vol. 57, No. Suppl. 11, 1996, pp. 68-71.
Paul E. Keck, Jr., et al., “Bipolar Disorder,” Medical Clinics of North America, W. B. Saunders Company, Philadelphia, US., vol. 3, No. 85, May 2001, pp. 645-661.
Maria-Garcia-Anaya et al., Los antipsycoticos atipicos: Una Revisión, Salud Mental, vol. 24, No. 5, Oct. 2001, pp. 37-43.
Yamada et al., Society for Neuroscience Abstracts (2000), 26 (1-2). No.—871.7.
“Unique Pharmacological Profile of a Novel Antipyschotic Drug, Aripiprazole (OPC-14597)” M. Sasa et al., CNS Drug Reviews, 1997, vol. 3, No. 1, pp. 24-33.
“Effects of Antidepressants on 5-HT7Receptor Regulation in the Rat Hypothalamus,” U. L. Mullins et al., Neuropsychopharmacology, 1999, vol. 21, No. 3, pp. 352-367.
“Alterations of Central Serotonin and Dopamine Turnover in Rats Treated with Ipsapirone and Other 5-Hydroxytryptamine1AAgonists with Potential Anxiolytic Properties1,” M. Hamon et al., J. Pharmacol. Exp. Ther., 1988, vol. 246, No. 2, pp. 745-752.
“Synthesis and Structure-Activity Relationship of Substituted Tetrahydro- and Hexahydro-1,2-benzisothiasol-3-one 1,1-Dioxides and Thiadiazinones: Potential Anxiolytic Agents,” M. Abou-Gharbia et al., J. Med. Chem., 1989, Vo. 32, No. 5, pp. 1024-1033.
H. Y. Meltzer et al., “Multisystems and Circuitry Pharmacotherapy—Single or Multiple Receptor Targets: Which are Best for Antipsychotic Drugs,” Neuropsychopharmacology 2000, vol. 23, No. 52.
Alfieri et al., “Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients,” British Journal of Cancel, vol. 72, 1995, pp. 1013-1015.
L.R.C. Agnew et al., “Dorland's illustrated medical dictionary, 24thEdition,” 1965, W:B: Saunders Company, Philadelphia, p. 1088.
Tsutomu Inoue et al., “Effects of Novel Antipsychotic Agent 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on Prolactin Release from the Rat Anterior Pituitary Gland,” The Journal of Pharmacology and Experimental Therapeutics, vol. 277, No. 1, Apr. 1996, pp. 137-143.
T. Sumiyoshi et al., “Tandospirone, a serotonin-1A agonist, added to neuroleptic treatment enhances cognitive performance in schizophrenia,” Database accession No. PREV200200022926.
Paul J. Goodnick et al., “Aripiprazole: Profile on efficacy and safety,”Expert Opinion on Pharmacotherapy, (2002) vol. 3(12) pp. 1173-1781.
Mark H. Beers, M.D. et al., “The Merck Manual of Diagnosis and therapy, Seventeenth edition”, Merck Research Laboratories, Whitehouse Station, N.J., (1999) pp. 1513-1516.
Nanzando's Medical Dictionary, (1990), 17thEd., p. 1571.
Nico J. Stam et al., “Human Serotonin 5-HT7Receptor: Cloning and Pharmacological Characterisation of Two Receptor Variants,” FEBS Letters 413 (1997) 489-494.
Joyce L.W. Yau et al., “Impact of Adrenalectomy on 5- HT6and 5-HT7Receptor Gene Expression in the Rat Hippocampus,” Molecular Brain Research 45 (1997) 182-186.
Murasaki, Mitsukuni, “Recent Trend of Development of Psychoactive Drugs (2)—Antipsychotic Drugs,” Jpn. J. Psychopharmacol., 15(3), 191-210 (1995).
Lawler, Cindy P. et al., “Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes,” Neuropshychopharmacology, vol. 20, No. 6, p. 612-627 (1999).
Office Action in Japan Application No. 2002-560616 dated Nov. 13, 2007.
Abe, M. et al., “Effect of 5-{-[((2,S)-1,4-Benzodioxan-2-ylmethyl)amino]propoxy}-1,3-benzodioxole HCI (MKC-242), a Novel 5-HT1A-Receptor Agonist, on Aggressive Behavior and Marble Burying Behavior in Mice,” Jpn. J. Pharmacol. 76, 297-304 (1998).
Abraham, H.D. et al., “LSD-Like Panic From Ri

Affiliated with

Also associated with

Rating

5-HT1A receptor subtype agonist does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5-HT1A receptor subtype agonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-HT1A receptor subtype agonist will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4253676